<DOC>
	<DOC>NCT00794638</DOC>
	<brief_summary>The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.</brief_summary>
	<brief_title>A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Aggressive Bcell nonHodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender. Patients with the following histologically confirmed CD20(+) Bcell nonHodgkin's lymphoma: 1. Diffuse large Bcell lymphoma 2. Mantle cell lymphoma 3. Transformed lymphoma 4. Follicular lymphoma (Grade 3) Fail to CR in prior chemotherapy, or relapse following CR or recurrence following PR. Patients who are judged to carry no effect from the prior therapy (cancer chemotherapy, antibody therapy and radiation/ radiotherapy. Patients aged from 20 to 75 years at the time informed consent is obtained Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions) Patients who can be hospitalized during the first cycle Patients capable of personally giving voluntary informed consent in writing to participate in the study Patients who meet any of the following criteria will be excluded. Patients with serious complications (hepatic or renal failure) Patients with complications or medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease) Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or diarrhea) Patients positive for HBs antigen, HCV antibody, or HIV antibody Patients who received other investigational drug or unapproved medication within 3 months before registration in this study Patients who had history of hematopoietic stem cell transplantation or radioimmunotherapy Patients who are pregnant, of childbearing potential, or lactating Patients, whether male or female, who do not agree to contraception Patients otherwise judged by investigator or sub investigator to be unsuitable</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Non-Hodgkin's Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Mantle cell Lymphoma</keyword>
	<keyword>Transformed lymphoma, transformed to diffuse large B-cell lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
</DOC>